Putensen Daniel, Smith Richard, Pilcher Linda, Trandafir George
University College London Hospitals, Apheresis Department, Macmillian Cancer Centre, University College London Hospitals, London, WC1E 6AG 02034471804, United Kingdom.
J Clin Apher. 2018 Jun;33(3):349-356. doi: 10.1002/jca.21618. Epub 2018 Feb 21.
An increasing demand for human lymphocytes require an efficient, reliable and reproducible lymphocyte process. Here, we compare the Spectra Optia® CMNC protocol with the Optia MNC platform in unmobilised donor lymphocyte collections.
To establish and compare the feasibility, efficiency, and practicability of the two apheresis protocols.
Data was collected prospectively from 60 non-cytokine stimulate donors who underwent a total of 64 T-cell collection procedures. Of these, 24 procedures were performed in the CMNC cohort and 40 procedures in the MNC cohort. All donors in the CMNC group were related; all donors in the MNC group were donors from a registry. Donor characteristics, procedure parameters and cellular product content were analysed and compared.
Donor characteristics and full blood count results were comparable, except the median white blood cell count, which was higher in the CMNC cohort (6.87 vs. 5.58 ×10 /L, P < .005). This resulted in higher lymphocyte (1.95 vs. 1.57 ×10 /L, P < .009) and CD3+ cell counts (1476 vs. 1060/L, P < .02). A total blood volume processed of 2.0 resulted in i) run time (222 vs. 242 min), ii) product volume (192 vs. 183 ml), iii) platelet content (2140 vs. 1345 ×10 /ml, P < .003). CD3+ CE2 (%): 54.7 vs. 50.4.
The CMNC and MNC protocols are reliable, efficient and comparable in performance parameters and cell composition of final product, respectively. One advantages of the CMNC protocol is the potential ability to tailor the cell composition of the final product accordingly to demands from cell processing laboratories.
对人淋巴细胞的需求不断增加，这就需要一种高效、可靠且可重复的淋巴细胞处理方法。在此，我们在未动员的供体淋巴细胞采集中，将Spectra Optia® CMNC方案与Optia MNC平台进行比较。
建立并比较两种单采方案的可行性、效率和实用性。
前瞻性收集60例非细胞因子刺激供体的数据，这些供体共接受了64次T细胞采集程序。其中，24次程序在CMNC队列中进行，40次程序在MNC队列中进行。CMNC组的所有供体均为亲属；MNC组的所有供体均来自登记处。对供体特征、程序参数和细胞产品含量进行分析和比较。
供体特征和全血细胞计数结果具有可比性，但CMNC队列中的中位白细胞计数较高（6.87对5.58×10⁹/L，P <.005）。这导致淋巴细胞计数（1.95对1.57×10⁹/L，P <.009）和CD3⁺细胞计数（1476对1060/μL，P <.02）更高。处理2.0升全血体积导致：i）运行时间（222对242分钟），ii）产品体积（192对183毫升），iii）血小板含量（2140对1345×10⁹/毫升，P <.003）。CD3⁺ CE2（%）：54.7对50.4。
CMNC和MNC方案在性能参数和最终产品的细胞组成方面分别是可靠、高效且可比的。CMNC方案的一个优点是有可能根据细胞处理实验室的需求调整最终产品的细胞组成。
